Motexafin gadolinium
- Generic Name
- Motexafin gadolinium
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C52H72GdN5O14
- CAS Number
- 246252-06-2
- Unique Ingredient Identifier
- 0BG5NE3APZ
- Background
Motexafin gadolinium is studied in the treatment of cancer by Pharmacyclics. It may make tumor cells more sensitive to radiation therapy, improve tumor images using magnetic resonance imaging (MRI), and kill cancer cells. It belongs to the family of drugs called metalloporphyrin complexes. Also called gadolinium texaphyrin.
- Indication
Investigated for use/treatment in brain cancer, cancer/tumors (unspecified), lung cancer, and lymphoma (non-hodgkin's).
- Associated Conditions
- -
- Associated Therapies
- -
Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy
- Conditions
- Interventions
- First Posted Date
- 2010-03-08
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- American College of Radiology Imaging Network
- Target Recruit Count
- 440
- Registration Number
- NCT01082224
- Locations
- ๐บ๐ธ
Lahey Clinic Medical Center - Burlington, Burlington, Massachusetts, United States
๐บ๐ธAbramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
๐บ๐ธThe Methodist Hospital for Liver Disease and Transplant, Houston, Texas, United States
Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL
- Conditions
- First Posted Date
- 2008-08-14
- Last Posted Date
- 2012-05-18
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00734773
Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer
- Conditions
- First Posted Date
- 2008-07-17
- Last Posted Date
- 2014-01-10
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 20
- Registration Number
- NCT00717587
- Locations
- ๐บ๐ธ
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Temozolomide and Radiation Therapy in Treating Young Patients With Pontine Glioma
- Conditions
- First Posted Date
- 2007-08-09
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Target Recruit Count
- 43
- Registration Number
- NCT00514397
- Locations
- ๐ฌ๐ง
Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom
๐ฌ๐งAddenbrooke's Hospital, Cambridge, England, United Kingdom
๐ฌ๐งGreat Ormond Street Hospital for Children, London, England, United Kingdom
Motexafin Gadolinium and Radiation Therapy in Treating Young Patients With Pontine Glioma
- Conditions
- Interventions
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2018-01-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 64
- Registration Number
- NCT00387790
- Locations
- ๐บ๐ธ
Children's Oncology Group, Philadelphia, Pennsylvania, United States
Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere)
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 50
- Registration Number
- NCT00373204
- Locations
- ๐บ๐ธ
Wilshire Oncology Medical Group, La Verne, California, United States
๐บ๐ธUniversity of Rochester, Rochester, New York, United States
๐ท๐ธClinic for Pulmonary Diseases, Belgrade, Serbia
Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2018-03-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 118
- Registration Number
- NCT00305864
- Locations
- ๐บ๐ธ
Memorial Hospital, Carthage, Illinois, United States
๐บ๐ธMason District Hospital, Havana, Illinois, United States
๐บ๐ธUniversity of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2008-09-11
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 35
- Registration Number
- NCT00290004
- Locations
- ๐บ๐ธ
USC Norris Cancer Hospital, Los Angeles, California, United States
๐บ๐ธNorthwestern University, Chicago, Illinois, United States
๐บ๐ธScripps Cancer Center, San Diego, California, United States
Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer
- Conditions
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2007-03-05
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 43
- Registration Number
- NCT00134186
- Locations
- ๐บ๐ธ
Methodist Hospital, Houston, Texas, United States
Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer
- Conditions
- First Posted Date
- 2005-08-12
- Last Posted Date
- 2008-08-20
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 108
- Registration Number
- NCT00129844
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.